SCHEMBL29569822

SCHEMBL29569822

O=c1ccc(-c2ccc(OC(F)F)nc2)nn1Cc1nnc(-c2ccccc2)s1

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ MET P08581 9/20 0.40
▸ TP53 P04637 1/20 0.39
▸ PDE4A P27815 1/20 0.39
▸ PDE4B Q07343 1/20 0.39
▸ PDE4C Q08493 1/20 0.39
▸ PDE4D Q08499 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ GRIN1 Q05586 2/20 0.36
▸ GRIN2B Q13224 2/20 0.36
▸ HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23528627 1.00 MEN1 (0.41) MEN1KMT2AMETTP53PDE4A
SCHEMBL23528516 0.92 MET (0.40) MEN1KMT2AMETTP53GRIN1
SCHEMBL29570039 0.92 MET (0.40) MEN1KMT2AMETTP53GRIN1
SCHEMBL23528801 0.88 MEN1 (0.40) MEN1KMT2AMETTP53PDE4A
SCHEMBL23528573 0.87 MEN1 (0.46) MEN1KMT2AMETTP53PDE4A
SCHEMBL26527906 0.85 MET (0.41) MEN1KMT2AMETTP53PDE4A
SCHEMBL26999003 0.85 PDE4B (0.54) MEN1KMT2AMETTP53PDE4A
SCHEMBL26531101 0.82 MEN1 (0.44) MEN1KMT2AMETTP53PDE4A
SCHEMBL25438256 0.82 MEN1 (0.35) MEN1KMT2AMETTP53PDE4A
SCHEMBL28615567 0.79 GRIN2B (0.34) GRIN1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223278-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-07-10 — — US disclosed
US-12240831-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-03-04 — — US disclosed
US-12012395-B2 Pyridazinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2024-06-18 — — US disclosed
US-20240025879-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2024-01-25 — — US disclosed
US-20220106291-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2022-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12012395-B2 Pyridazinone compounds and uses thereof IL6, IL1B, IL1A MEN1 4368/4885KMT2A 4169/4885MET 4212/4885
US-12240831-B2 Pyridazinone compounds and uses thereof IL6, IL1B, IL1A MEN1 4368/4885KMT2A 4169/4885MET 4212/4885
US-20220106291-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A MEN1 4368/4885KMT2A 4169/4885MET 4212/4885
US-20250223278-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A MEN1 4368/4885KMT2A 4169/4885MET 4212/4885
US-20240025879-A1 PYRIDAZINONE COMPOUNDS AND USES THEREOF IL6, IL1B, IL1A MEN1 4368/4885KMT2A 4169/4885MET 4212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback